PPARA and metabolic dysfunction-associated steatohepatitis: While elafibranor did not exhibit a statistically significant effect on NASH resolution, other clinical trials with different co-agonists of PPAR are currently under investigation in NASH patients [PPARα/γ agonism (Saroglitazar, Zydus, phase II) and PPARα/γ/δ agonism (Lanifibranor, Inventiva, phase II), etc.].